Subgroup analysis of advanced lung cancer with CAO (n=43) or without CAO (n=42): demographic features, presenting features, histology, stage, therapy and outcomes
| Treated advanced lung cancer | |||
| With CAO requiring re-canalisation | Without CAO | p-value | |
| Age years | 63 (32–86) | 67 (48–84) | 0.49 |
| Sex male | 32 (74.4%) | 30 (71.4%) | 0.81 |
| Pleural effusion | |||
| Central airway obstruction | 43 (100%) | 0.0001 | |
| Presenting symptom | |||
| Cough | 17 (39.5%) | 25 (59.6%) | 0.08 |
| Dyspnoea | 25 (58.1%) | 14 (33.3%) | 0.02 |
| Respiratory failure | 15 (35%) | 0.0001 | |
| Intubation for respiratory failure | 10 (23.3%) | 0.001 | |
| Haemoptysis | 6 (14%) | 13 (31%) | 0.07 |
| Hoarseness | 0 | 3 (7.1%) | 0.11 |
| Histology | |||
| Adenocarcinoma | 13 (30.2%) | 17 (40.4%) | 0.36 |
| Squamous cell carcinoma | 16 (37.2%) | 3 (7.1%) | 0.001 |
| Non-small cell lung cancer | 8 (18.6%) | 9 (21.4%) | 0.79 |
| Small cell carcinoma | 3 (6.9%) | 7 (16.6%) | 0.18 |
| Sarcomatoid carcinoma | 2 (4.6%) | 1 (2.3%) | 1.0 |
| Others | 1 (2.3%) | 4 (9.5%) | 0.20 |
| Stage | |||
| Stage IIIA | 10 (23.3%) | 4 (9.6%) | 0.14 |
| Stage IIIB | 8 (18.7%) | 5 (12%) | 0.54 |
| Stage IV | 25 (58.2%) | 33 (78.6%) | 0.06 |
| Cancer specific therapy | |||
| Epidermal growth factor receptor mutation exon 19 and 21 | 4 (9.3%) | 4 (9.5%) | 1.0 |
| Chemotherapy | 11 (25.5%) | 23 (54.7%) | 0.008 |
| Radiotherapy | 20 (46.5%) | 21 (50%) | 0.82 |
| TKI | 4 (9.3%) | 9 (21.4%) | 0.14 |
| Survival | |||
| Deaths | 32 (74.4%) | 40 (95.2%) | 0.26 |
| Survival months | 5.8 (0.32–62) | 9.3 (0.8–78.3%) | 0.30 |
| <3 months | 13 (30.3%) | 11 (26.2%) | 1.0 |
| ≥3 months | 30 (69.8%) | 31 (73.9%) | 0.81 |
| ≥6 months | 20 (46.6%) | 27 (64.3%) | 0.12 |
| ≥12 months | 13 (30.3%) | 15 (35.7%) | 0.64 |
| >24 months | 5 (11.7%) | 4 (9.6%) | 1.0 |
| ≥5 year | 1 (2.3%) | 2 (4.7%) | 0.61 |
Data are presented as median (range) unless otherwise stated. CAO: central airway obstruction; TKI: tyrosine kinase inhibitor.